Abstract: System, methods, and devices for initializing a system by loading drivers are provided. In one example, a system includes comprising one or more circuits to initiate a system initiation or a boot of the system, during the system initiation or the boot of the system, read data from a non-volatile memory, based on the data from the non-volatile memory, identify a plurality of hardware components, identify one or more drivers based on the plurality of hardware components, and load the one or more drivers during the system initiation or the boot of the system.

Abstract: The present disclosure provides Compound (1), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Compound (1) is used as an enhancer and/or modifier of an immune response (e.g., innate and/or adaptive immune response), and is useful in treating and/or preventing a disease, as an adjuvant in a vaccine for a disease, (e.g., a proliferative disease, an inflammatory disease, an autoimmune disease, an infectious disease, an allergy, a fibrotic disease, a cardiovascular disease, a graft rejection, graft-versus-host disease, chronic disease, or addiction), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are vaccines, pharmaceutical compositions, kits, methods, and uses including or using Compound (1).

Abstract: Provided herein are thiazole amide compounds (e.g., Formula (I)) for use in enhancing human immune response and/or as adjuvants in vaccines. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are compositions (e.g., pharmaceutical composition), kits, methods, and uses including or using compounds described herein.

Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: A system for connecting cage-side connectors to PCB-side connectors. The system enables OSFP and QSFP pluggable modules to be connected to breakouts on PCBs within a networking device. The system includes one or more cage-side connectors connected via one or more cables to one or more PCB-side connectors. Keyed PCB-side connectors and unique lengths of cables ensure proper connections to headers on a PCB.

Abstract: A system for connecting cage-side connectors to PCB-side connectors. The system enables OSFP and QSFP pluggable modules to be connected to breakouts on PCBs within a networking device. The system includes one or more cage-side connectors connected via one or more cables to one or more PCB-side connectors. Keyed PCB-side connectors and unique lengths of cables ensure proper connections to headers on a PCB.

Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: System, methods, and devices for initializing a system by loading drivers are provided. In one example, a system includes comprising one or more circuits to initiate a system initiation or a boot of the system, during the system initiation or the boot of the system, read data from a non-volatile memory, based on the data from the non-volatile memory, identify a plurality of hardware components, identify one or more drivers based on the plurality of hardware components, and load the one or more drivers during the system initiation or the boot of the system.

Abstract: A network device includes a plurality of ports, a plurality of optical indicators, two or more packet processing circuits, and synchronization circuitry. The two or more packet processing circuits are to process packets communicated over the ports, each packet processing circuit to control a subset of the optical indicators to display status information relating to a subset of the ports. At least some of the status information is represented by blinking of the optical indicators. The synchronization circuitry is to synchronize at least one operational characteristic of the optical indicators among the two or more packet processing circuits.

Abstract: Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described for proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease, in a subject in need thereof. Using the compound as a vaccine adjuvant enables effective immunization in vulnerable populations.

Abstract: Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described.

Abstract: A cable pillar is provided for use in a switch system. The cable pillar includes a cavity that enables a plurality of cables to pass from a first side to a second side of the cable pillar. For example, the cables may be routed from sets of access paths located in rails mounted on the sides of the cable pillar to enlarged access paths located near the top or bottom of the cable pillar. The enlarged access paths may be sized to receive every cable that passes through a set of access paths located on an opposing side of the cable pillar from a corresponding enlarged access path. Additionally, the cable pillar may be configured to releasably attach to a chassis of the switch system. In some examples, the plurality of cables accommodated by the cable pillar may serve as a cable backplane of the switch system.

Abstract: According to at least some embodiments of the present invention is directed to anti-HIDE1 antibodies and polypeptides and methods of using same.

Abstract: A dual connect switch module may include a first set of pluggable panel connectors on a first side of a substrate of the switch and a second set of pluggable panel connectors on an opposing second side of the substrate. The switch module further includes a switch Integrated Circuit (IC) mounted between the first side and the second side, where the switch IC is connected to the first set of pluggable panel connectors and to the second set of pluggable panel connectors. A cable can be used to connect at least one pluggable panel connector of the first set of pluggable panel connectors and/or of the second set of pluggable panel connectors with a port of an external network device. In some examples, the switch and substrate may further include a management module that manages one or more on-board functions of the switch module.

Abstract: Provided herein are adjuvantation systems comprising fungal polysaccharides for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) and influenza (influenza A virus and influenza B virus) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus or influenza virus antigen.

Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.

Abstract: The present invention is directed to PVRIG polypeptides and their uses.

Abstract: The invention is a dust control substances-solution (DCSS). The invention discloses the substances the DCSS is made of, how they are to be mixed and how the DCSS is to be applied. The DCSS is based on treated soft wood particles and substances that form a layer oved dust covered surfaces. The layer “traps” water that is applied to the surface, thus, maintaining the dust in aggregates and prevents its raising to the air.

Abstract: A system for connecting cage-side connectors to PCB-side connectors. The system enables OSFP and QSFP pluggable modules to be connected to breakouts on PCBs within a networking device. The system includes one or more cage-side connectors connected via one or more cables to one or more PCB-side connectors. Keyed PCB-side connectors and unique lengths of cables ensure proper connections to headers on a PCB.

Abstract: The present invention is directed to PVRIG polypeptides and their uses.